Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Eifer

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2026
Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 TherapyRaghava Kashyap, James P Buteau, Nathan Papa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry AnalysisDavid C Chen, James P Buteau, Nathan Papa, et al.
The Lancet. Oncology|July 5, 2025
First-in-human results of terbium-161 [<sup>161</sup>Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 studyJames P Buteau, Louise Kostos, Price A Jackson, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2026
Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 TherapyRaghava Kashyap, James P Buteau, Nathan Papa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry AnalysisDavid C Chen, James P Buteau, Nathan Papa, et al.
The Lancet. Oncology|July 5, 2025
First-in-human results of terbium-161 [<sup>161</sup>Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 studyJames P Buteau, Louise Kostos, Price A Jackson, et al.
Pageof 3